Literature DB >> 8020228

Bone formation in the presence of phagocytosable hydroxyapatite particles.

J S Wang1, S Goodman, P Aspenberg.   

Abstract

Small particles of biomaterials used in orthopaedic surgery have been shown to induce the resorption of bone. The purpose of this study was to determine whether phagocytosable particles of hydroxyapatite had an adverse effect on bone ingrowth. Bone harvest chambers were implanted bilaterally in the proximal tibial metaphyses of 13 mature rabbits. The bone harvest chamber has a transverse 1-mm wide pore, providing a continuous canal through the chamber for tissue ingrowth. After an initial 6-week period for osseointegration of the bone harvest chambers, the contents of the canal were harvested at 3-or 6-week intervals. Hydroxyapatite particles (diameter, 5 mu) were mixed with a carrier solution, 1% sodium hyaluronate, and implanted in the canal of one chamber in each animal. The contralateral chamber was implanted with the carrier only and served as a control. Histological sections from the tissue harvested from the chambers were evaluated by light microscopy and histomorphometry, and the area of bone ingrowth was measured as a percentage of total area in each section. At 3 weeks there was more bone in the hydroxyapatite sections than in controls; at 6 weeks there was no difference. Hydroxyapatite particles were incorporated within the matrix of new ingrown bone at both time periods. There was no evidence of granuloma formation or inflammation. Previous studies have shown that particles of high density polyethylene and bone cement adversely affect bone ingrowth in this model. The present results suggest that hydroxyapatite particles, small enough to be phagocytosed by macrophages, did not have such effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8020228

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  7 in total

1.  Osteoporotic vertebral compression fractures augmentation by injectable partly resorbable ceramic bone substitute (Cerament™|SPINE SUPPORT): a prospective nonrandomized study.

Authors:  Salvatore Masala; Giovanni Nano; Stefano Marcia; Mario Muto; Francesco Paolo Maria Fucci; Giovanni Simonetti
Journal:  Neuroradiology       Date:  2011-08-11       Impact factor: 2.804

2.  Osteoporotic vertebral compression fracture augmentation by injectable partly resorbable ceramic bone substitute (Cerament™|SPINESUPPORT): a prospective nonrandomized study.

Authors:  Salvatore Masala; Giovanni Nano; Stefano Marcia; Mario Muto; Francesco P M Fucci; Giovanni Simonetti
Journal:  Neuroradiology       Date:  2012-03-06       Impact factor: 2.804

Review 3.  On the fate of particles liberated from hydroxyapatite coatings in vivo.

Authors:  C F Dunne; J Gibbons; D P FitzPatrick; K J Mulhall; K T Stanton
Journal:  Ir J Med Sci       Date:  2015-01-10       Impact factor: 1.568

4.  In vitro and in vivo biological responses to a novel radiopacifying agent for bone cement.

Authors:  J S Wang; J Diaz; A Sabokbar; N Athanasou; F Kjellson; K E Tanner; I D McCarthy; L Lidgren
Journal:  J R Soc Interface       Date:  2005-03-22       Impact factor: 4.118

5.  Factors influencing the compressive strength of an injectable calcium sulfate-hydroxyapatite cement.

Authors:  M Nilsson; L Wielanek; J-S Wang; K E Tanner; L Lidgren
Journal:  J Mater Sci Mater Med       Date:  2003-05       Impact factor: 3.896

6.  The effect of a biphasic injectable bone substitute on the interface strength in a rabbit knee prosthesis model.

Authors:  Vasilis Zampelis; Magnus Tägil; Lars Lidgren; Hanna Isaksson; Isam Atroshi; Jian-Sheng Wang
Journal:  J Orthop Surg Res       Date:  2013-07-31       Impact factor: 2.359

7.  Tissue reaction and material biodegradation of a calcium sulfate/apatite biphasic bone substitute in rat muscle.

Authors:  Jian-Sheng Wang; Magnus Tägil; Hanna Isaksson; Mathias Boström; Lars Lidgren
Journal:  J Orthop Translat       Date:  2015-12-19       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.